Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LANTERN: QVA149 vs Fluticasone/Salmeterol in COPD
NCT01709903Phase 3Completed
- Sponsor
- Novartis
- Start
- Nov 2012
- Primary completion
- Feb 2014
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial of indacaterol + glycopyrronium in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Novartis. Primary endpoint: Trough Forced Expiratory Volume in One Second (FEV1) to Demonstrate Non-inferiority at 26 weeks. Started Nov 2012; status: completed.
02
Drugs
indacaterol + glycopyrronium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT01709903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01709903.